Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ionis Buys Out Akcea As Cardiovascular Pipeline Blooms

Executive Summary

The RNA-drug developer, which is buying the approximately 24% of Akcea it doesn't already own for around $500m, highlighted the maturing pipeline in a cardiovascular overview.

You may also be interested in...



Deal Watch: Kite Inks Novel AML Target Discovery Tie-Up With HiFiBiO

Continuing parent firm Gilead’s busy deal-making year in immuno-oncology, Kite gets option rights to new targets. Boehringer teams with Israel’s BiomX in IBD research.

As FDA Decision Nears, Novartis Highlights New Analysis Of Blockbuster Hopeful Inclisiran

Novartis has pooled cholesterol control and safety data, but will have to wait longer for cardiovascular outcomes readout.

New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs

Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel